Patient-derived immunocompetent cultures reveal personalized immunotherapies and new treatment options for therapy resistant patients with high-grade serous ovarian cancer

被引：0
|
作者：
Farkkila, Anniina
Nagaraj, Ashwini S.
Pietila, Elina A.
Salko, Matilda
Erkan, Erdogan P.
Niemiec, Iga
Sirsikar, Aditi
Bao, Jie
Marchi, Giovanni
Nowlan, Kirsten
Hautaniemi, Sampsa
Vaharautio, Anna
Tang, Jing
Haltia, Ulla-Maija
Kekalainen, Eliisa
Virtanen, Anni
Salo, Tuula
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 05期
关键词：
D O I：
10.1158/1538-7445.OVARIAN23-PR-007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PR-007
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A Potential New Treatment for High-Grade Glioma: A Study Assessing Repurposed Drug Combinations against Patient-Derived High-Grade Glioma Cells
    Lastakchi, Sarah
    Olaloko, Mary Kanyinsola
    McConville, Christopher
    CANCERS, 2022, 14 (11)
  • [42] New prognostic index for neoadjuvant chemotherapy outcome in patients with advanced high-grade serous ovarian cancer
    Huo, Chuying
    Wu, Bin
    Ye, Dongdong
    Xu, Miaochun
    Ma, Shaolin
    Cheng, Aoshuang
    Liu, Yunyun
    Huang, Chunxian
    Zhang, Yuhao
    Lin, Zhongqiu
    Li, Bowen
    Lu, Huaiwu
    BMC CANCER, 2024, 24 (01)
  • [43] Establishing patient derived organoids for high-grade serous ovarian cancer as representative models for pre-clinical research
    Clark, James J.
    Krell, Jon
    Dickie, Catriona
    Kondyliou, Lydia
    Lorentzen, Marc
    Lythgoe, Mark
    Miron-Barroso, Sofia
    Gater, Lucy
    Januskeviciute, Rugile
    Fotopoulou, Christina
    Cunnea, Paula
    CANCER RESEARCH, 2024, 84 (05)
  • [44] A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management
    Bradbury, Melissa
    Borras, Eva
    Vilar, Marta
    Castellvi, Josep
    Luis Sanchez-Iglesias, Jose
    Perez-Benavente, Assumpcio
    Gil-Moreno, Antonio
    Santamaria, Anna
    Sabido, Eduard
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
  • [45] A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management
    Melissa Bradbury
    Eva Borràs
    Marta Vilar
    Josep Castellví
    José Luis Sánchez-Iglesias
    Assumpció Pérez-Benavente
    Antonio Gil-Moreno
    Anna Santamaria
    Eduard Sabidó
    Journal of Translational Medicine, 20
  • [46] Antibody-drug conjugate targeting folate receptor α: a new milestone in personalized medicine for high-grade serous ovarian cancer
    Gonzalez-Martin, Antonio
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (08) : 1126 - 1127
  • [47] Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients
    Anna P. Sokolenko
    Tatiana V. Gorodnova
    Ilya V. Bizin
    Ekaterina Sh. Kuligina
    Khristina B. Kotiv
    Alexandr A. Romanko
    Tatiana I. Ermachenkova
    Alexandr O. Ivantsov
    Elena V. Preobrazhenskaya
    Tatiana N. Sokolova
    Robert V. Broyde
    Evgeny N. Imyanitov
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 439 - 450
  • [48] Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients
    Sokolenko, Anna P.
    Gorodnova, Tatiana, V
    Bizin, Ilya, V
    Kuligina, Ekaterina Sh
    Kotiv, Khristina B.
    Romanko, Alexandr A.
    Ermachenkova, Tatiana, I
    Ivantsov, Alexandr O.
    Preobrazhenskaya, Elena, V
    Sokolova, Tatiana N.
    Broyde, Robert, V
    Imyanitov, Evgeny N.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (03) : 439 - 450
  • [49] Activity of the MEK inhibitor Binimetinib (MEK162) in combination with paclitaxel in patient-derived xenograft models of high-grade serous ovarian carcinoma
    Winski, Shannon L.
    Bouhana, Karyn
    Rhodes, Susan
    Cable, LouAnn
    Anderson, Deborah
    Williams, Lance
    Tunquest, Brian
    Logan, Tiffany
    Vigers, Guy
    Lee, Patrice
    CANCER RESEARCH, 2015, 75
  • [50] Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
    Iavarone, Claudia
    Zervantonakis, Ioannis K.
    Selfors, Laura M.
    Palakurthi, Sangeetha
    Liu, Joyce F.
    Drapkin, Ronny
    Matulonis, Ursula A.
    Hallbergs, Dorothy
    Velculescu, Victor E.
    Leverson, Joel D.
    Sampath, Deepak
    Mills, Gordon B.
    Brugge, Joan S.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (03) : 642 - 655
12345